Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B

Exact Sciences Corp. was acquired by Abbott Laboratories for approximately $20.6 billion on March 23, 2026, marking a major consolidation in cancer diagnostics.

Exact Sciences Corp., a leader in cancer screening technologies, was acquired by Abbott Laboratories in a $20.6 billion deal completed on March 23, 2026. The transaction, funded primarily by $20.0 billion in long-term notes, gives Abbott control over the $60 billion U.S. cancer screening market, according to Fixed Income Beacon as of March 2026.

Prior to the acquisition, Exact Sciences reported its latest quarterly earnings on February 13, 2026, posting EPS of ($0.21), missing consensus estimates of $0.08 by $0.29, while revenue grew 23.1% year-over-year, per MarketBeat as of February 13, 2026. The deal underscores strategic shifts in the diagnostics sector relevant to US investors tracking healthcare M&A.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Exact Sciences Corporation
• Sector/industry: Healthcare / Cancer Diagnostics
• Headquarters/country: United States
• Core markets: US cancer screening
• Key revenue drivers: Cologuard tests, precision oncology
• Home exchange/listing venue: Nasdaq (EXAS)
• Trading currency: USD

Exact Sciences Corp.: core business model

Exact Sciences Corp. specializes in non-invasive cancer screening and precision diagnostics, with its flagship Cologuard test revolutionizing colorectal cancer detection since FDA approval in 2014. The company generates revenue primarily through molecular tests that detect cancer biomarkers in stool samples, targeting the US market where colorectal cancer remains a leading cause of death. This model has positioned it as a key player for US investors interested in preventive healthcare innovations.

Listed on Nasdaq under ticker EXAS, the firm expanded into multi-cancer early detection with tests like Cancerguard, focusing on high-risk populations. Its business relies on direct-to-consumer marketing and partnerships with healthcare providers, driving adoption in the $60 billion US screening sector now bolstered by the Abbott acquisition.

Main revenue and product drivers for Exact Sciences Corp.

Cologuard remains the primary revenue driver, accounting for the bulk of sales with 23.1% year-over-year growth reported for the quarter ended December 31, 2025 (published February 13, 2026). Precision oncology solutions, including Oncotype DX, contribute through genomic profiling for breast and other cancers, enhancing Exact Sciences' portfolio amid rising demand for personalized medicine in the US.

Therascreen and other lab services support recurring revenue, with total figures reflecting strong volume growth despite profitability challenges, as seen in the recent net margins of -6.40% for the trailing period per MarketBeat data as of February 2026.

Industry trends and competitive position

The cancer diagnostics market is expanding rapidly due to aging US demographics and screening guideline expansions, with Exact Sciences holding a strong foothold via Cologuard's proven efficacy. Competitors like Guardant Health and Illumina vie for share, but the Abbott deal enhances Exact Sciences' scale in liquid biopsy and screening tech.

Why Exact Sciences Corp. matters for US investors

With Nasdaq listing and heavy US revenue exposure, Exact Sciences exemplifies growth in American healthcare innovation. The acquisition integrates it into Abbott's portfolio, potentially stabilizing earnings for investors eyeing defensive medtech plays amid economic shifts.

Conclusion

The $20.6 billion acquisition by Abbott on March 23, 2026, caps a transformative period for Exact Sciences Corp., highlighted by robust revenue growth but ongoing profitability hurdles in its Q4 2025 results. US investors will watch how this integration unfolds in the competitive diagnostics landscape, balancing innovation potential with execution risks in cancer screening.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.